Sourasky Medical Center (Ichilov)
| Израиль | Түркия | Австрия | |
| Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау | бастап $135,000 | бастап $80,000 | бастап $180,000 |
| Туыстық донордан алынған сүйек кемігін аллогендік трансплантациялау | бастап $142,000 | бастап $65,000 | бастап $150,000 |
| Сүйек кемігін трансплантациялау | бастап $144,000 | бастап $36,000 | бастап $140,000 |
Дәрігер туралы ақпарат қазіргі уақытта жаңартылуда. Доктор Рон Сураски медициналық орталығында (Ихилов) жұмыс істейді.
Доктор Рам Сураски медициналық орталығында дің жасушаларын трансплантациялау бойынша бірнеше жүз ота жасады. Бұл процедура апластикалық анемияны емдеудің негізгі әдісі болып табылады.
300-ден астам жілік майы мен кіндік қанын трансплантациялау — доктор Эль Хасид Дана Двек балалар ауруханасында балалар онкогематологиясы бөлімшесін басқарады.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Primary treatment for aplastic anemia in Israel centers on bone marrow transplantation and advanced immunosuppressive therapy. JCI-accredited facilities provide allogeneic transplants from both related and unrelated donors. Specialized protocols include ATG, cyclosporine, and Eltrombopag for refractory cases. High success rates are supported by precise HLA matching and molecular diagnostics.
Bookimed Expert Insight: Israeli centers offer a significant advantage in donor matching through international registry access and specialized pediatric expertise. For example, Dr. Ronit El Hasid at Sourasky Medical Center has performed over 300 pediatric transplants. At Sheba Medical Center, packages around $160,000 include extensive 30-day hospitalizations. This level of integrated care is critical because recovery requires intensive monitoring that shorter stays may not provide.
Patient Consensus: Patients note it is important to start HLA typing immediately to speed up the transplant process. Many emphasize that while fatigue during recovery is challenging, having a strong support network helps manage long-term monitoring needs.
Israeli hospitals like Sourasky Medical Center, Sheba Medical Center, and Hadassah Medical Center are world leaders in treating aplastic anemia. These JCI-accredited facilities specialize in allogeneic bone marrow transplants and advanced immunosuppressive therapy. They achieve success rates reaching 90% for complex hematological cases.
Bookimed Expert Insight: Choosing between top centers often comes down to specific pediatric expertise versus adult volume. While Sheba Medical Center serves over 1,500,000 global patients annually, Sourasky offers highly specialized pediatric care at Dana-Dwek. Dr. Ronit El Hasid at Sourasky has performed over 300 successful transplantations specifically for children. Patients should compare these volume-based success rates when selecting a facility for rare blood disorders.
Patient Consensus: Patients note that Israeli hospitals excel at finding matches through international registries. They also emphasize the importance of having a translator to help navigate the intake process and hospital bureaucracy.
Israeli medical centers report survival rates exceeding 90% for bone marrow transplantation in young aplastic anemia patients. Success stays near 90.8% for those under age 40. Specialized protocols for alternative donor types maintain outcomes as high as 94% in leading facilities.
Bookimed Expert Insight: Israeli hematology departments offer a significant advantage through high-volume specialization. For example, Dr. Ivetta Danylesko at Sheba Medical Center has performed 3,000 procedures. This level of individual experience often correlates with the high survival rates reported across the country's major JCI-accredited institutions.
Patient Consensus: Patients emphasize that bone marrow transplant is often the preferred first-line treatment over immunosuppression for younger people. Many note that blood counts typically begin to normalize by day 100 with proper monitoring.
Hospitalization for a bone marrow transplant in Israel typically lasts 30 days. Patients remain in specialized HEPA-filtered rooms to prevent infections while the new immune system develops. Full physical recovery and immune rebuilding generally require 3 to 12 months of follow-up care.
Bookimed Expert Insight: While many focus on the surgery, the 30-day hospital stay included in Sheba Medical Center packages is a critical safety benchmark. High-volume centers like Sourasky, which serves over 400,000 patients annually, use this extended period to manage the delicate transition before home discharge. Selecting a package that builds in 4 weeks of inpatient care ensures professional monitoring during the highest-risk window for rejection.
Patient Consensus: Patients note it is important to pack for at least 6 weeks of hospital stay to stay comfortable. Many emphasize that recovery is not always a straight line, as the first 100 days require constant bloodwork and home help.
Candidacy for aplastic anemia treatment in Israel depends on donor availability, patient age, and disease severity. Patients under 40 with a matched sibling donor typically receive bone marrow transplants as a curative first-line therapy. Immunosuppressive therapy serves as the primary alternative when no related donor is identified.
Bookimed Expert Insight: While many believe international registries are the only option, top Israeli centers like Sheba and Rambam maintain advanced facilities for bone marrow cell collection and storage. This infrastructure allows for a more flexible transition from drug therapy to transplant if initial treatments do not produce a 90% success rate. Clinics like Sourasky Medical Center also offer specialized pediatric protocols, where Dr. Ronit El Hasid has performed over 300 successful transplants, often combining standard care with newer medications to improve outcomes.
Patient Consensus: Patients emphasize the necessity of completing a full donor search, including both siblings and global registries, before starting drug therapy. Many note that delays in medication availability can sometimes make a transplant the faster and more reliable recovery path.
International patients have full access to donor matching and unrelated-donor searches in Israel through the World Marrow Donor Association. Israeli centers routinely coordinate with global registries like the National Marrow Donor Program to identify compatible donors worldwide. This process ensures high-quality matching for complex cases.
Bookimed Expert Insight: While many search processes take months, Israeli hospitals like Sheba and Sourasky serve over 1.5 million patients annually, giving them immense logistical leverage. Our data shows that top-tier packages, which cost around $150,000 to $160,000, often include extensive diagnostics and 30-day hospital stays. High-volume centers like Sheba pioneered cord-blood transplants, providing a vital alternative when a 10/10 unrelated donor match is unavailable through standard registries.
Patient Consensus: Patients note it is vital to start the unrelated-donor search immediately through home registries to speed up acceptance at Israeli centers. Coordination with local international programs helps manage the 6–8 month lead time and logistics for 10/10 matches.
Post-treatment follow-up for aplastic anemia includes coordinated care between Israeli hematologists and local providers. Patients undergo frequent blood panels and bone marrow biopsies to monitor for relapse. Institutions like Sheba Medical Center and Hadassah Medical Center utilize telemedicine to review progress and adjust medications remotely.
Bookimed Expert Insight: While major centers like Sourasky or Hadassah provide comprehensive discharge summaries, the actual coordination often depends on the specific specialist. Dr. Ron Ram at Sourasky and Dr. Polina Stepensky at Hadassah are known for managing complex transplant protocols. Their patients should confirm follow-up visit inclusions in their $150,000 to $160,000 packages, as these often cover the first critical post-operative reviews within Israel before departure.
Patient Consensus: Patients note it is important to track your own labs and keep copies of all blood work. They emphasize establishing a local hematologist before leaving Israel for seamless care.